Beeline Medicines
PVT · PVT·Stamford, CT·Private·Phase 2
Debuted in April 2026 with $300M in Series A financing led by Bain Capital, bringing five autoimmune/inflammatory programs licensed from Bristol Myers Squibb. Building a precision immunology platform spanning clinical-stage small molecules and biologics for lupus, atopic dermatitis, psoriasis, and GI inflammation. Led by former SpringWorks CEO Saqib Islam.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Beeline Medicines website | Website | May 5, 2026 | 2 |